var data={"title":"Sildenafil: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sildenafil: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6951?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sildenafil-drug-information\" class=\"drug drug_general\">see &quot;Sildenafil: Drug information&quot;</a> and <a href=\"topic.htm?path=sildenafil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sildenafil: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220995\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Revatio;</li>\n      <li>Viagra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220996\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Revatio;</li>\n      <li>Viagra</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1035851\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Phosphodiesterase Type-5 (PDE5) Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445030\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> In pediatric patients (1 to 17 years of age) with PAH, an increased mortality risk was associated with long-term use (&gt;2 years) at dosage levels of 0.88 to 2.5 mg/kg/dose administered three times daily (Barst, 2012; Barst, 2012a); use of Revatio, especially chronic use, is not recommended in pediatric patients due to a dose-dependent increased mortality risk observed in trials; however, situations may exist in which the benefit-risk profile of Revatio may make its use, with close monitoring, acceptable in individual pediatric patients, for example, when other treatment options are limited. Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pulmonary hypertension: </b>\n      <b>Note:</b> Limited data available; dose not established; a wide range of doses and interpatient variability has been reported; careful dose titration is necessary; most literature consists of case reports or small studies.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Full-term neonates: Usual range: 0.5 to 3 mg/kg/dose every 6 to 12 hours; the largest study was a double-blind, randomized, placebo-controlled trial and used an initial dose of 3 mg/kg/dose every 6 hours in 31 patients (Vargas-Origel, 2010); earlier studies used 0.3 to 2 mg/kg/dose every 6 to 24 hours; optimal duration not established (Ahsman, 2009; Baquero, 2006; Noori, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: GA &gt;34 weeks and PNA &lt;72 hours: PPHN: 0.4 mg/kg loading dose administered over 3 hours followed by continuous infusion of 1.6 mg/kg/<b>day</b> for up to 7 days was used in four patients in an open-label, dose-escalation trial of 36 neonates with an oxygenation index (OI) &ge;15 on two occasions at least 30 minutes apart; 29 patients were also receiving iNO (Steinhorn, 2009); <b>Note:</b> The dose listed here is the dose recommended by the authors for use in future clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who previously failed iNO wean):</b> <b>Note:</b> Limited information exists; a wide range of doses and interpatient variability has been reported; careful dose titration is necessary; most literature consists of case reports or small studies.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Full-term neonates:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Single dose: ~0.3 mg/kg/dose given once 70 to 90 minutes prior to iNO discontinuation was used in three patients (3 days, 6 weeks, and 4 months of age) (Atz, 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Multiple dose: Initial: 0.3 mg/kg/dose (range: 0.22 to 0.47 mg/kg/dose) every 6 hours (average duration: 28 days) was used in seven patients (median age: 12 months; range: 3 days to 21 months); optimal duration of treatment not established (Lee, 2008). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1035889\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sildenafil-drug-information\" class=\"drug drug_general\">see &quot;Sildenafil: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> In pediatric patients (1 to 17 years of age) with PAH, an increased mortality risk was associated with long-term use (&gt;2 years) at dosage levels of 0.88 to 2.5 mg/kg/dose administered three times daily (Barst, 2012; Barst, 2012a); use of Revatio, especially chronic use, is not recommended in pediatric patients due to a dose-dependent increased mortality risk observed in trials; however, situations may exist in which the benefit-risk profile of Revatio may make its use, with close monitoring, acceptable in individual pediatric patients, for example, when other treatment options are limited. Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary hypertension:</b> Limited data available; dose and duration of therapy not established; interpatient variability has been reported; Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: Initial: 0.25 mg/kg/dose every 6 hours <b>or</b> 0.5 mg/kg/dose every 8 hours; titrate as needed; maximum reported dose range: 1 to 2 mg/kg/dose every 6 to 8 hours (Humpl, 2011; Mourani, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">An open-label, prospective trial of 25 pediatric patients &lt;5 years of age (median age: 6 months; age range: 10 days to 4.9 years) reported statistically significant improvement in echocardiography outcome measures; in 15 patients, sildenafil abolished rebound pulmonary hypertension following NO withdrawal; the initial dose of 0.25 mg/kg/dose four times daily was titrated as tolerated to a target of 1 mg/kg/dose four times daily; the reported median dose was 0.7 mg/kg/dose four times daily (range: 0.5 to 2.25 mg/kg/dose); reported duration of therapy was 9 days to 4.3 years (n=25); 11 patients were discontinued on sildenafil therapy due to clinical resolution; nine deaths were reported [severe lung hypoplasia (n=3); veno-occlusive disease post-chemotherapy (n=1); severe BPD (n=1); cause of death unrelated to pulmonary vascular disease (n=4)] (Humpl, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">A retrospective trial of 25 pediatric patients &lt;2 years of age (which included at least 16 infants) evaluated long-term safety and efficacy in patients with chronic lung disease (72% with BPD); at therapy initiation, the subject ages ranged from 14 days to 96 weeks (median: ~6 months); the initial dose of 0.5 mg/kg/dose every 8 hours was titrated as tolerated; the majority of patients were treated with 8 mg/kg/<b>day</b> (2 mg/kg/dose four times daily); echocardiogram showed clinical improvement in 88% of patients; reported duration of therapy was 28 to 950 days (median: 241 days); five deaths were reported during therapy (day 25 to 241 of therapy; median: 135 days); causes of death included sepsis, meningitis, and refractory respiratory disease (Mourani, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents &lt;18 years of age: <b>Note:</b> Dosage should not be increased; higher doses and long-term use are associated with an increased mortality risk (Barst, 2012; Barst, 2012a).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">8 to 20 kg: 10 mg three times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;20 kg to 45 kg: 20 mg three times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;45 kg: 40 mg three times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosing based on the STARTS-1 and 2 trial, a randomized, double-blind, placebo-controlled study in 235 pediatric patients (1 to 17 years of age) which evaluated short-term and long-term safety and efficacy of 3 dose levels (low, medium, and high-dose); results suggested that the medium dose level (shown above) is efficacious at improving exercise capacity, functional class and hemodynamic status in the short-term (16 weeks duration); the low dosage level was not shown to be efficacious. The long-term safety and efficacy data showed a dose-dependent increased risk of mortality which was highest among the high-dose group. It was estimated that the dosing presented will produce serum concentration of 140 ng/mL and would be expected to inhibit 77% of phosphodiesterase type 5 activity <i>in vitro</i> (Barst, 2012; Barst, 2012a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary hypertension, congenital heart surgery (postoperative):</b> Limited data available; dosing regimens variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (or nasogastric tube): Infants, Children, and Adolescents: Initial: 0.5 mg/kg/dose upon admission to ICU; increase in 0.5 mg/kg/dose increments every 4 to 6 hours up to a maximum dose of 2 mg/kg/dose as tolerated; upon discontinuation of mechanical ventilation, sildenafil therapy can be tapered over 5 to 7 days; dosing based on a retrospective report of 100 pediatric patients (including neonates through &gt;10 years of age) which showed reduction in pulmonary arterial pressures and/or prevention of severe pulmonary hypertension (Nemoto, 2010). A lower dose of 0.35 mg/kg/dose every 4 hours for 1 week postoperatively was used in a retrospective, case-controlled trial of 38 pediatric patients (age range: 5 to 33 months) (Palma, 2011). In another retrospective report (n=45, median age: 32.6 months; range: 6 days to 17 years), a mean dose of 0.9 &plusmn; 0.3 mg/kg/dose four times daily was reported (Uhm, 2010). <b>Note:</b> Use of preoperative sildenafil therapy for the prevention of pulmonary hypertension following congenital heart surgery has produced variable efficacy results (Palma, 2011); a double-blind, placebo-controlled trial showed a negative impact on oxygenation and ventricular function (Vassalos, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants &gt;60 days and Children: Loading dose: Range: 0.04 to 0.35 mg/kg administered over 5 minutes, followed by a maintenance infusion: Reported range: 0.015 to 0.4 mg/kg/<b>hour</b> continued for 24 to 72 hours was used for pulmonary hypertension occurring within 48 hours of the end of cardiac surgery in a multicenter, randomized, double-blind, placebo-controlled dose-finding trial (n=17; median age: 5 months; age range: 3 months to 14 years; neonates and infants &lt;60 days were excluded from the trial); dosages were either low, medium, or high dose (n=4 each treatment group; n=5 placebo) designed to attain serum concentrations of 40, 120, and 360 ng/mL, respectively; patients receiving sildenafil at all dosages were found to have lower pulmonary artery pressure and when compared to placebo, shorter duration of mechanical ventilation (median: 3 days vs 8 days), shorter ICU stay (median: 6 days vs 15 days), and shorter hospitalization (median: 12 days vs 21 days); study closed early due to slow patient accrual leading to underpowered results; no conclusions about dosage were able to be determined (Fraisse, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who have <span style=\"text-decoration: underline\">not</span> previously failed iNO wean):</b> Limited data available: Infants and Children &le;15 months: Oral: Single dose: 0.4 mg/kg/dose (range: 0.3 to 0.5 mg/kg/dose) given once 60 minutes prior to iNO discontinuation; dosing based on a randomized, double-blind, placebo-controlled trial in 29 infants and young children (median age: 5.6 months; age range: 1 to 15 months; n=15 treatment arm) (Namachivayam, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erectile dysfunction</b> (Viagra): Oral: Usual: 50 mg taken as needed, ~1 hour before sexual activity (dose may be taken 30 minutes to 4 hours before sexual activity); dosing range: 25 to 100 mg once daily; maximum recommended dose: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary arterial hypertension</b> (Revatio):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 5 mg or 20 mg 3 times daily taken at least 4-6 hours apart; maximum recommended dose: 20 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 2.5 mg or 10 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage considerations for patients taking alpha blockers:</b> There are no pediatric-specific recommendations; in adult patients, dosing adjustment suggested.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant use of potent CYP34A inhibitors: </b> There are no pediatric-specific recommendations; in adult patients receiving Revatio, the following dosing adjustment suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Strong CYP3A inhibitors (eg, itraconazole, ketoconazole): Not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Protease inhibitors: Concurrent use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Revatio: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Viagra: No dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Revatio: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Viagra: Starting dose of 25 mg should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh classes A and B):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Revatio: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Viagra: Starting dose of 25 mg should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Revatio: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Viagra: Starting dose of 25 mg should be considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220969\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio: 10 mg/12.5 mL (12.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/12.5 mL (12.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio: 10 mg/mL (112 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viagra: 25 mg, 50 mg, 100 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg, 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220955\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1035894\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Revatio: Administer doses at least 4 to 6 hours apart; may be administered without regard to meals; shake oral suspension well prior to use; <b>Note:</b> Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe provided by the manufacturer only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe will  need to be dispensed. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Viagra: Administer with or without food 30 minutes to 4 hours before sexual activity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Revatio:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: In clinical trials, loading dose was administered over 3 hours, followed by a continuous IV infusion (Steinhorn, 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infant, Children, and Adolescents: In clinical trials, loading dose was administered as a bolus over 5 minutes, followed by a continuous IV infusion (Fraisse, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Administer as an IV bolus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220990\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets/injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions are permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral suspension: Store unreconstituted powder below 30&deg;C (86&deg;F); protect from moisture. Store reconstituted oral suspension below 30&deg;C (86&deg;F) or at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze. Discard unused Revatio oral suspension after 60 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1035852\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of WHO Group I pulmonary arterial hypertension (PAH) (Revatio: FDA approved in adults); treatment of erectile dysfunction (Viagra: FDA approved in male adults). Has also been used for treatment of persistent pulmonary hypertension of the newborn (PPHN) refractory to treatment with inhaled nitric oxide; facilitation of weaning from nitric oxide (ie, to attenuate rebound effects after discontinuing inhaled nitric oxide); secondary pulmonary hypertension following cardiac surgery; <b>Note:</b> Use of Revatio, especially chronic use, is not recommended in pediatric patients due to a dose-dependent increased mortality risk observed in trials; however, situations may exist in which the benefit-risk profile of Revatio may make its use, with close monitoring, acceptable in individual pediatric patients, for example, when other treatment options are limited.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221036\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revatio may be confused with ReVia, Revonto</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sildenafil may be confused with silodosin, tadalafil, vardenafil</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viagra may be confused with Allegra, Vaniqa</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221034\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Based upon normal doses for either indication or route. (Adverse effects such as flushing, diarrhea, myalgia, and visual disturbances may be increased with adult doses &gt;100 mg/24 hours.)</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness, headache, insomnia, paresthesia</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Dermatologic: Erythema, skin rash</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea, dyspepsia, gastritis, nausea</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection </p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Hepatic: Increased liver enzymes</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain, myalgia</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Ophthalmic: Visual disturbance (including vision color changes, blurred vision, and photophobia)</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Respiratory: Epistaxis, exacerbation of dyspnea, nasal congestion, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abnormal hepatic function tests, absent reflexes, amnesia (transient global), anemia, anorgasmia, anterior chamber eye hemorrhage, anterior ischemic optic neuropathy, arthritis, auditory impairment, basal cell carcinoma (Loeb 2015), breast hypertrophy, burning sensation of eyes, cardiac failure, cataract, cerebrovascular hemorrhage, colitis, cystitis, depression, diaphoresis, diplopia, dry eye syndrome, dysphagia, ECG abnormality, ejaculatory disorder, exfoliative dermatitis, falling, gastroenteritis, genital edema, gingivitis, glossitis, gout, herpes simplex infection, hyperglycemia, hypernatremia, hypersensitivity reaction, hypertension, hypertonia, hypoglycemia, increased bronchial secretions, increased intraocular pressure, ischemic heart disease, laryngitis, leukopenia, malignant melanoma (Li 2014; Loeb 2015), migraine, myasthenia, mydriasis, myocardial infarction, neuralgia, neuropathy, orthostatic hypotension, otalgia, peripheral edema, pharyngitis, photophobia, priapism, prolonged erection, pulmonary hemorrhage, rectal hemorrhage, retinal edema, retinal hemorrhage, retinal vascular disease, rupture of tendon, seizure, severe sickle cell crisis (vaso-occlusive crisis in patients with pulmonary hypertension associated with sickle cell disease), skin photosensitivity, stomatitis, syncope, synovitis, tachycardia, transient ischemic attacks, unstable diabetes, urinary incontinence, ventricular arrhythmia, vitreous detachment, vitreous traction </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220974\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate); concomitant use of riociguat (a guanylate cyclase stimulator).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">According to the manufacturers of protease inhibitors  (atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir): Concurrent use with a protease inhibitor regimen when sildenafil is used for pulmonary artery hypertension (eg, Revatio).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Viagra: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Revatio: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION); concurrent use with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir); pulmonary hypertension secondary to sickle cell anemia; severe hepatic impairment; recent history of stroke or MI, or life-threatening arrhythmia; coronary artery disease causing unstable angina; severe hypotension (&lt;90/50 mm Hg) at initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220959\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hearing loss: Sudden decrease or loss of hearing has been reported; hearing changes may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including rash, urticaria, anaphylactic reaction, and anaphylactic shock, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Decreases in blood pressure may occur due to vasodilator effects; use with caution in patients with left ventricular outflow obstruction (aortic stenosis, hypertrophic obstructive cardiomyopathy), those on antihypertensive therapy, with resting hypotension (BP &lt;90/50 mm Hg), fluid depletion, or autonomic dysfunction; may be more sensitive to hypotensive actions. Patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. Monitor blood pressure when combining with medications that lower blood pressure. Substantial consumption of ethanol may increase the risk of hypotension and orthostasis. Lower ethanol consumption has not been associated with significant changes in blood pressure or increase in orthostatic symptoms. Have patients avoid or limit ethanol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Painful erection &gt;6 hours in duration has been reported rarely. Educate patient to seek medical assistance for erection lasting &gt;4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vision loss: Sudden loss of vision in one or both eyes, including permanent loss of vision, may occur and be a sign of nonarteritic anterior ischemic optic neuropathy (NAION). Risk may be increased with history of vision loss. Other risk factors for NAION include low cup-to-disc ratio (&ldquo;crowded disc&rdquo;), coronary artery disease, diabetes, hypertension, hyperlipidemia, smoking, and &gt;50 years of age. Patients suffering sudden vision loss should discontinue therapy and consult health care provider immediately. A direct relationship between therapy and vision loss has not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders; safety has not been established. <i>In vitro</i> studies have suggested a decreased effect on platelet aggregation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with hypotension (&lt;90/50 mm Hg); uncontrolled hypertension (&gt;170/110 mm Hg); life-threatening arrhythmias, stroke or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina; safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). There is a degree of cardiac risk associated with sexual activity; therefore, health care providers should consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conditions predisposing to priapism: Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia). All patients should be instructed to seek immediate medical attention if erection persists &gt;4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use Viagra with caution in patients with hepatic impairment; use lowest starting dose (25 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; PAH: Sudden cessation of sildenafil monotherapy could result in an exacerbation of PAH. Efficacy in adult patients determined through short-term (12-16 week) studies; safety of longer-term use is unclear. A long-term use trial in pediatric patients showed increased mortality in the higher dose groups (20-80 mg [depending upon weight] 3 times/day) after 2 years of use (Barst 2012a; Barst 2012b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary veno-occlusive disease: Use in patients with pulmonary veno-occlusive disease (PVOD) is not recommended (has not been studied); if pulmonary edema occurs when treating pulmonary arterial hypertension (PAH), consider the possibility of PVOD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use Viagra with caution in patients with renal impairment; dose adjustment may be needed; use lowest starting dose (25 mg) in severe dysfunction (CrCl &lt;30 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell anemia: Treatment of pulmonary hypertension with sildenafil in this patient population may lead to more hospitalizations for management of vaso-occlusive crises. The effectiveness and safety of sildenafil have not been established in pulmonary hypertension secondary to sickle cell disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nitrates: Use of sildenafil is contraindicated in patients currently taking nitrate preparations. However, when nitrate administration becomes medically necessary, the ACCF/AHA 2013 guidelines on treatment of ST-segment elevation MI and the ACCF/AHA 2012 guidelines on treatment of unstable angina/non ST-segment elevation MI support administration of nitrates only if 24 hours have elapsed after use of sildenafil (ACCF/AHA [Anderson 2013]; ACCF/AHA [O'Gara 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use of Revatio, especially chronic use, is not recommended in children. After 2 years of treatment, increased mortality was seen in a long-term (median treatment exposure: 4.6 years) study at higher doses (20 to 80 mg [depending upon weight] 3 times/day) (Barst 2012a; Barst 2012b).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; dose adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suspension: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe provided by the manufacturer only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe will need to be dispensed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: In the treatment of erectile dysfunction potential underlying causes of erectile dysfunction should be evaluated prior to initiating sildenafil treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitations of use: In the treatment of pulmonary arterial hypertension the addition of sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221022\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220964\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13000&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective).  Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Sildenafil. Management: Avoid sildenafil when used for treatment of pulmonary arterial hypertension in patients receiving boceprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg every other day with close monitoring for sildenafil toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Phosphodiesterase 5 Inhibitors may increase the serum concentration of Bosentan.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Sildenafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary hypertension should be avoided with strong CYP3A4 inhibitors.  When used for erectile dysfunction, starting adult dose should be reduced to 25 mg.  Maximum adult dose with ritonavir or cobicistat is 25 mg per 48 hours.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of Sildenafil. Management: For pulmonary arterial hypertension, US label recommends no dose adjustment and Canadian label recommends reducing to 20mg twice/day.  For erectile dysfunction, consider using a lower starting dose of 25mg in patients who are also taking erythromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Management: No empiric dosage adjustments are recommended with concomitant therapy; however, dose of the phosphodiesterase inhibitor may need to be altered based on clinical response.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Sildenafil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Sildenafil. Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Sildenafil. Management: Concurrent ketoconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lorcaserin: May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: May increase the serum concentration of Sildenafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Sildenafil. Management: Concurrent posaconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent posaconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: May increase the serum concentration of Sildenafil. Management: Used for PAH: no dose adjustment recommended per US label, Canadian label recommends decrease to 20 mg twice/day. Used for ED: consider a lower starting dose of 25 mg with concurrent saquinavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Sildenafil. Management: Concurrent use of sildenafil for treatment of pulmonary arterial hypertension is contraindicated with telaprevir.  Sildenafil for erectile dysfunction should be limited to 25 mg per 48 hours, with close monitoring for sildenafil toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of Sildenafil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Sildenafil. Management: Concurrent voriconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent voriconazole.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220991\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Grapefruit juice may increase serum levels/toxicity of sildenafil. Management: Avoid grapefruit juice. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220978\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to the use of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in pregnant women is limited (Cartago 2014; Hsu 2011; Wollein 2016). Women with pulmonary arterial hypertension are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014). Because sildenafil causes vasodilation in the uterus, it is currently under study for various obstetric uses (Dunn 2016; Dunn 2017; Pels 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930483\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Heart rate, blood pressure, oxygen saturation, PaO<sub>2</sub></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220958\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Erectile dysfunction: Does not directly cause penile erections, but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Pulmonary arterial hypertension (PAH): Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220973\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Erectile dysfunction: ~60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Decrease blood pressure: Oral: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Erectile dysfunction: 2 to 4 hours; Decrease blood pressure: &lt;8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid; slower with a high-fat meal; tablet and suspension are bioequivalent </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into tissues</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub> total: Neonates: 22.4 L (or 456 L/70 kg) (Mukherjee 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> V<sub>dss</sub>: Adults: 105 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: Sildenafil: 93.9% &plusmn; 2.5%; N-desmethyl metabolite: 92% &plusmn; 3% (Mukherjee 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Sildenafil and N-desmethyl metabolite: ~96% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4 (major) and CYP2C9 (minor route); major metabolite (UK-103320 or desmethylsildenafil) is formed via N-desmethylation pathway and has 50% of the activity as sildenafil </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: Mean: 41%; range: 25% to 63%; may be higher in patients with PAH compared to healthy volunteers; <b>Note:</b> A 10 mg dose of the injection is predicted to have an effect equal to a 20 mg oral dose taking into consideration the parent drug and active metabolite </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sildenafil: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: PNA 1 day: 55.9 hours (Mukherjee 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: PNA 7 days: 47.7 hours (Mukherjee 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Active N-desmethyl metabolite: Terminal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Neonates: 11.9 hours (Mukherjee 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: Fasting: 30 to 120 minutes (median 60 minutes); delayed by 60 minutes with a high-fat meal </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (~80%, as metabolites); urine (~13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Decreased in patients with hepatic cirrhosis or severe renal impairment; clearance may be lower in patients with PAH compared to normal volunteers. Sildenafil clearance in newborns is significantly decreased compared to adults, but approaches adult (allometrically scaled) values by the first week of life (Mukherjee 2009). Clearance of N-desmethyl active metabolite is decreased in patients with severe renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2619373\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral suspension is available (10 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 2.5 mg/mL sildenafil citrate oral suspension may be made with tablets and either a 1:1 mixture of methylcellulose 1% and simple syrup NF or a 1:1 mixture of Ora-Sweet and Ora-Plus. Crush thirty sildenafil 25 mg tablets (Viagra) in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to <b>almost</b> 300 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 300 mL. Store in amber plastic bottles and label &quot;shake well&quot;. Stable for 90 days at room temperature or refrigerated.</p>\n    <div class=\"reference\">Nahata MC, Morosco RS, and Brady MT, &ldquo;Extemporaneous Sildenafil Citrate Oral Suspensions for the Treatment of Pulmonary Hypertension in Children,&rdquo; <i>Am J Health-Syst Pharm</i>, 2006, 63(3):254-7.<span class=\"pubmed-id\">16434784</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220977\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Revatio Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/12.5 mL (12.5 mL): $251.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sildenafil Citrate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/12.5 mL (12.5 mL): $220.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Revatio Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (112 mL): $9,883.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Revatio Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $5,151.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sildenafil Citrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,800.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $1,993.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $1,993.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $1,993.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Viagra Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $2,424.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $2,424.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $2,424.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F220980\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acmegra (BD);</li>\n      <li>Adegra (BD);</li>\n      <li>Adonix (PH);</li>\n      <li>Amfidor (CZ);</li>\n      <li>Andros (PH);</li>\n      <li>Androz (ET);</li>\n      <li>Aphrodil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Avigra (ZW);</li>\n      <li>Avixar (LV);</li>\n      <li>Azulsix (ES);</li>\n      <li>Balcoga (CZ);</li>\n      <li>Blugral (IE);</li>\n      <li>Bultis Film (KR);</li>\n      <li>Canova (ZW);</li>\n      <li>Caprenafil (ID);</li>\n      <li>Cilafil (AT);</li>\n      <li>Cupid (ET, VN);</li>\n      <li>Direktan (AT);</li>\n      <li>Dragul (ES);</li>\n      <li>Ecriten (LV);</li>\n      <li>Edegra (IN, SG);</li>\n      <li>Edyfil (MY);</li>\n      <li>Ejertol (CO);</li>\n      <li>Elonza (MY, TH);</li>\n      <li>Ereccil (PY);</li>\n      <li>Erecstar (EC);</li>\n      <li>Erectol (AR);</li>\n      <li>Erilin (CO);</li>\n      <li>Ernafil (HK, SG);</li>\n      <li>Eromaks (UA);</li>\n      <li>Eroton (BG);</li>\n      <li>Eroxim (CO);</li>\n      <li>Facsid (LK);</li>\n      <li>Fexion (ES);</li>\n      <li>For MR. (KR);</li>\n      <li>Fortera Orally Soluble Film (KR);</li>\n      <li>Freeya (KR);</li>\n      <li>Funcional (EC);</li>\n      <li>Grandipam (CZ);</li>\n      <li>Happigra Gran (KR);</li>\n      <li>Hippigra (HK);</li>\n      <li>Hydenex (PH);</li>\n      <li>Idilico (AT);</li>\n      <li>Immense (BD);</li>\n      <li>Iqnyde (MY);</li>\n      <li>Ivagra (LK);</li>\n      <li>Kamagra (ET, ZW);</li>\n      <li>Katora (CZ);</li>\n      <li>Lekap (TR);</li>\n      <li>Maxigra (HK);</li>\n      <li>Neo-Up (PH);</li>\n      <li>Nipatra (GB);</li>\n      <li>Olvion (RO, SG);</li>\n      <li>Osigra (LK);</li>\n      <li>Pahtension (KR);</li>\n      <li>Palpal Chew Tab (KR);</li>\n      <li>Patrex (SE);</li>\n      <li>Penegra (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, PH, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Pramil (PY);</li>\n      <li>Pronafil (PH);</li>\n      <li>Pulmolan (AT);</li>\n      <li>Remenafil (SG);</li>\n      <li>Revatio (AT, AU, BB, BE, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JP, KR, LT, LU, LV, MT, MY, NL, NZ, PL, PT, RO, RU, SE, SI, SK, TH, TR, TW);</li>\n      <li>Rigix (PY);</li>\n      <li>Ripol (CL);</li>\n      <li>Sanbenafil (ID);</li>\n      <li>Seregra (ZW);</li>\n      <li>Serivia Gran (KR);</li>\n      <li>Sidegra (TH);</li>\n      <li>Sidena (IE);</li>\n      <li>Silagra (ET);</li>\n      <li>Silatio (TH);</li>\n      <li>Silchemo (AT);</li>\n      <li>Sildefil (AR);</li>\n      <li>Sildegra (SG);</li>\n      <li>Silvie (KR);</li>\n      <li>Supra (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Syldokad (UA);</li>\n      <li>Tagazepin (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tigerfil (HK, PH);</li>\n      <li>Tonafil (TH);</li>\n      <li>Topgra (ID);</li>\n      <li>V-Gra (BD);</li>\n      <li>Varonil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vasigra (LK);</li>\n      <li>Viagra (AE, AT, AU, BB, BE, BF, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NZ, OM, PA, PE, PH, PL, PT, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Viahra (UA);</li>\n      <li>Viajoy (ID);</li>\n      <li>Viasin Powder (KR);</li>\n      <li>Viner (HR);</li>\n      <li>Vivic (HK, MY);</li>\n      <li>Vizarsin (IE, MT, PL);</li>\n      <li>Willmon-100 (HK);</li>\n      <li>Wingora (PH);</li>\n      <li>X-cite (BD);</li>\n      <li>Xcite (LK);</li>\n      <li>Xex (EC);</li>\n      <li>Zilden (PH);</li>\n      <li>Zwagra (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Al Hadithy AF, de Goede AL, Eckhardt M, et al, &quot;Stability of Sildenafil (Revatio&reg;) Dilutions in Dextrose 5%,&quot; <i>Intensive Care Med</i>, 2011, 37(11):1899.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/21946926/pubmed\" target=\"_blank\" id=\"21946926\">21946926</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahsman MJ, Witjes BC, Wildschut ED, et al, &quot;Sildenafil Exposure in Neonates With Pulmonary Hypertension After Administration Via a Nasogastric Tube,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2010, 95(2):F109-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/19949232/pubmed\" target=\"_blank\" id=\"19949232\">19949232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apitz C, Reyes JT, Holtby H, et al, &quot;Pharmacokinetic and Hemodynamic Responses to Oral Sildenafil During Invasive Testing in Children With Pulmonary Hypertension,&quot; <i>J Am Coll Cardiol</i>, 2010, 55(14):1456-62. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/20359596/pubmed\" target=\"_blank\" id=\"20359596\">20359596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atz AM and Wessel DL, &quot;Sildenafil Ameliorates Effects of Inhaled Nitric Oxide Withdrawal,&quot; <i>Anesthesiology</i>, 1999, 91(1):307-10. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/10422958/pubmed\" target=\"_blank\" id=\"10422958\">10422958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Badesch DB, Abman SH, Simonneau G, et al, &ldquo;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2007, 131(6):1917-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/17565025/pubmed\" target=\"_blank\" id=\"17565025\">17565025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baquero H, Soliz A, Neira F, et al, &quot;Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study,&quot; <i>Pediatrics</i>, 2006, 117(4):1077-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/16585301/pubmed\" target=\"_blank\" id=\"16585301\">16585301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Ivy DD, Gaitan G, et al, &quot;A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension,&quot; <i>Circulation</i>, 2012, 125(2):324-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/22128226/pubmed\" target=\"_blank\" id=\"22128226\">22128226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barst RJ, Layton GR, Konourina I, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-na&iuml;ve patients with pediatric pulmonary arterial hypertension.<i>Eur Heart Jour</i>. 2012;33:979.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/24637559/pubmed\" target=\"_blank\" id=\"24637559\">24637559</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carroll WD and Dhillon R, &quot;Sildenafil as a Treatment for Pulmonary Hypertension,&quot; <i>Arch Dis Child</i>, 2003, 88(9):827-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/12937112 /pubmed\" target=\"_blank\" id=\"12937112 \">12937112 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erickson S, Reyes J, Bohn D, et al, &quot;Sildenafil (Viagra) in Childhood and Neonatal Pulmonary Hypertension,&quot; <i>J Am Coll Cardiol</i>, 2002, 39(Suppl):S402.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraisse A and Wessel DL, &quot;Acute Pulmonary Hypertension in Infants and Children: cGMP-Related Drugs,&quot; <i>Pediatr Crit Care Med</i>, 2010, 11(2 Suppl):S37-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/20216161/pubmed\" target=\"_blank\" id=\"20216161\">20216161</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haworth SG and Hislop AA, &quot;Treatment and Survival in Children With Pulmonary Arterial Hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006,&quot; <i>Heart</i>, 2009, 95(4):312-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/18952635/pubmed\" target=\"_blank\" id=\"18952635\">18952635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humpl T, Reyes JT, Erickson S, et al, &quot;Sildenafil Therapy for Neonatal and Childhood Pulmonary Hypertensive Vascular Disease,&quot; <i>Cardiol Young</i>, 2011, 21(2):187-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/21138617/pubmed\" target=\"_blank\" id=\"21138617\">21138617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Humpl T, Reyes JT, Holtby H, et al, &quot;Beneficial Effect of Oral Sildenafil Therapy on Childhood Pulmonary Arterial Hypertension: Twelve-Month Clinical Trial of a Single-Drug, Open-Label, Pilot Study,&quot; <i>Circulation</i>, 2005, 111(24):3274-80. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/15956137/pubmed\" target=\"_blank\" id=\"15956137\">15956137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hsu CH, Gomberg-Maitland M, Glassner C, et al, &quot;The Management of Pregnancy and Pregnancy-Related Medical Conditions in Pulmonary Arterial Hypertension Patients,&quot; <i>Int J Clin Pract Suppl</i>, 2011, 172:6-14. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/21736676/pubmed\" target=\"_blank\" id=\"21736676\">21736676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karatza AA, Bush A, and Magee AG, &quot;Safety and Efficacy of Sildenafil Therapy in Children With Pulmonary Hypertension,&quot; <i>Int J Cardiol</i>, 2005, 100(2):267-73. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/15823634/pubmed\" target=\"_blank\" id=\"15823634\">15823634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karatza AA, Narang I, Rosenthal M, et al, &quot;Treatment of Primary Pulmonary Hypertension With Oral Sildenafil,&quot; <i>Respiration</i>, 2004, 71(2):192-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/15031578/pubmed\" target=\"_blank\" id=\"15031578\">15031578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&ouml;nig K and Henschke P, &quot;Successful Weaning of Nitric Oxide Facilitated by a Single Dose of Sildenafil in a Baby With Persistent Pulmonary Hypertension of the Newborn,&quot; <i>Pediatr Pulmonol</i>, 2009, 44(8):837. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/19598230/pubmed\" target=\"_blank\" id=\"19598230\">19598230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kothari SS and Duggal B, &quot;Chronic Oral Sildenafil Therapy in Severe Pulmonary Artery Hypertension,&quot; <i>Indian Heart J</i>, 2002, 54(4):404-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/12462669/pubmed\" target=\"_blank\" id=\"12462669\">12462669</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krishnan U, Krishnan S, and Gewitz M, &quot;Treatment of Pulmonary Hypertension in Children With Chronic Lung Disease With Newer Oral Therapies,&quot; <i>Pediatr Cardiol</i>, 2008, 29(6):1082-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/18594787/pubmed\" target=\"_blank\" id=\"18594787\">18594787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lammers AE, Haworth SG, and Pierce CM, &quot;Intravenous Sildenafil as an Effective Treatment of Pulmonary Hypertensive Crises During Acute Intestinal Malabsorption,&quot; <i>Cardiol Young</i>, 2006, 16(1):84-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/16454884/pubmed\" target=\"_blank\" id=\"16454884\">16454884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JE, Hillier SC, and Knoderer CA, &quot;Use of Sildenafil to Facilitate Weaning From Inhaled Nitric Oxide in Children With Pulmonary Hypertension Following Surgery for Congenital Heart Disease,&quot; <i>J Intensive Care Med</i>, 2008, 23(5):329-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/18701525/pubmed\" target=\"_blank\" id=\"18701525\">18701525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. <i>JAMA</i>. 2015;313(24):2449-2455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/26103029/pubmed\" target=\"_blank\" id=\"26103029\">26103029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marsh CS, Marden B, and Newsom R, &quot;Severe Retinopathy of Prematurity (ROP) in a Premature Baby Treated With Sildenafil Acetate (Viagra) for Pulmonary Hypertension,&quot; <i>Br J Ophthalmol</i>, 2004, 88(2):306-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/14736800 /pubmed\" target=\"_blank\" id=\"14736800 \">14736800 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association,&rdquo;<i> J Am Coll Cardiol</i>, 2009, 53(17):1573-619. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/19389575/pubmed\" target=\"_blank\" id=\"19389575\">19389575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mourani PM, Sontag MK, Ivy DD, et al, &quot;Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants With Chronic Lung Disease,&quot; <i>J Pediatr</i>, 2009, 154(3):379-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/18950791/pubmed\" target=\"_blank\" id=\"18950791\">18950791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mukherjee A, Dombi T, Wittke B, et al, &quot;Population Pharmacokinetics of Sildenafil in Term Neonates: Evidence of Rapid Maturation of Metabolic Clearance in the Early Postnatal Period,&quot; <i>Clin Pharmacol Ther</i>, 2009, 85(1):56-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/18800037/pubmed\" target=\"_blank\" id=\"18800037\">18800037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nagdyman N, Fleck T, Bitterling B, et al, &quot;Influence of Intravenous Sildenafil on Cerebral Oxygenation Measured by Near-Infrared Spectroscopy in Infants After Cardiac Surgery,&quot; <i>Pediatr Res</i>, 2006, 59(3):462-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/16492990/pubmed\" target=\"_blank\" id=\"16492990\">16492990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Namachivayam P, Theilen U, Butt WW, et al, &quot;Sildenafil Prevents Rebound Pulmonary Hypertension After Withdrawal of Nitric Oxide in Children,&quot; <i>Am J Respir Crit Care Med</i>, 2006, 174(9):1042-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/16917115/pubmed\" target=\"_blank\" id=\"16917115\">16917115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nemoto S, Sasaki T, Ozawa H, et al, &quot;Oral Sildenafil for Persistent Pulmonary Hypertension Early After Congenital Cardiac Surgery in Children,&quot; <i>Eur J Cardiothorac Surg</i>, 2010, 38(1):71-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/    20206543/pubmed\" target=\"_blank\" id=\"    20206543\">    20206543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noori S, Friedlich P, Wong P, et al, &quot;Cardiovascular Effects of Sildenafil in Neonates and Infants With Congenital Diaphragmatic Hernia and Pulmonary Hypertension,&quot; <i>Neonatology</i>, 2007, 91(2):92-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/17344658/pubmed\" target=\"_blank\" id=\"17344658\">17344658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palma G, Giordano R, Russolillo V, et al, &quot;Sildenafil Therapy for Pulmonary Hypertension Before and After Pediatric Congenital Heart Surgery,&quot; <i>Tex Heart Inst J</i>, 2011, 38(3):238-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/21720460/pubmed\" target=\"_blank\" id=\"21720460\">21720460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pierce CM, Petros AJ, and Fielder AR, &quot;No Evidence for Severe Retinopathy of Prematurity Following Sildenafil,&quot; <i>Br J Ophthalmol</i>, 2005, 89(2):250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/15665374/pubmed\" target=\"_blank\" id=\"15665374\">15665374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raja SG, Danton MD, MacArthur KJ, et al, &quot;Effects of Escalating Doses of Sildenafil on Hemodynamics and Gas Exchange in Children With Pulmonary Hypertension and Congenital Cardiac Defects,&quot;<i> J Cardiothorac Vasc Anesth</i>, 2007, 21(2):203-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/17418732/pubmed\" target=\"_blank\" id=\"17418732\">17418732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raposo-Sonnenfeld I, Otero-Gonz&aacute;lez I, Blanco-Aparicio M, et al, &quot;Treatment With Sildenafil, Bosentan, or Both in Children and Young People With Idiopathic Pulmonary Arterial Hypertension and Eisenmenger's Syndrome,&quot; <i>Rev Esp Cardiol</i>, 2007, 60(4):366-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/17521545/pubmed\" target=\"_blank\" id=\"17521545\">17521545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revatio (sildenafil) [prescribing information]. New York, NY: Pfizer Labs; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samada K, Shiraishi H, Aoyagi J, et al, &quot;Cerebral Hemorrhage Associated With Sildenafil (Revatio) in an Infant,&quot; <i>Pediatr Cardiol</i>, 2009, 30(7):998-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/19582500/pubmed\" target=\"_blank\" id=\"19582500\">19582500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh TP, Rohit M, Grover A, et al, &quot;A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Efficacy of Oral Sildenafil Therapy in Severe Pulmonary Artery Hypertension,&quot; <i>Am Heart J</i>, 2006, 151(4):851.e1-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/16569546/pubmed\" target=\"_blank\" id=\"16569546\">16569546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spillers J, &quot;PPHN: Is Sildenafil the New Nitric? A Review of the Literature,&quot; <i>Adv Neonatal Care</i>, 2010, 10(2):69-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/20386371/pubmed\" target=\"_blank\" id=\"20386371\">20386371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steinhorn RH, Kinsella JP, Pierce C, et al, &quot;Intravenous Sildenafil in the Treatment of Neonates With Persistent Pulmonary Hypertension,&quot; <i>J Pediatr</i>, 2009, 155(6):841-847.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/19836028/pubmed\" target=\"_blank\" id=\"19836028\">19836028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uhm JY, Jhang WK, Park JJ, et al, &quot;Postoperative Use of Oral Sildenafil in Pediatric Patients With Congenital Heart Disease,&quot; <i>Pediatr Cardiol</i>, 2010, 31(4):515-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/20054528/pubmed\" target=\"_blank\" id=\"20054528\">20054528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vargas-Origel A, G&oacute;mez-Rodr&iacute;guez G, Aldana-Valenzuela C, et al, &quot;The Use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn,&quot; <i>Am J Perinatol</i>, 2010, 27(3):225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/19866403/pubmed\" target=\"_blank\" id=\"19866403\">19866403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vassalos A, Peng E, Young D, et al, &quot;Pre-Operative Sildenafil and Pulmonary Endothelial-Related Complications Following Cardiopulmonary Bypass: A Randomised Trial in Children Undergoing Cardiac Surgery,&quot; <i>Anaesthesia</i>, 2011, 66(6):472-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sildenafil-pediatric-drug-information/abstract-text/21457152/pubmed\" target=\"_blank\" id=\"21457152\">21457152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viagra (sildenafil) [prescribing information]. New York, NY: Pfizer Labs; March 2014.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13000 Version 216.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F220995\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F220996\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1035851\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445030\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1035889\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F220969\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F220955\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1035894\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F220990\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1035852\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F221036\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221034\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F220974\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F220959\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F221022\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F220964\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F220991\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F220978\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2930483\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F220958\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F220973\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F2619373\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F220977\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F220980\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13000|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sildenafil-drug-information\" class=\"drug drug_general\">Sildenafil: Drug information</a></li><li><a href=\"topic.htm?path=sildenafil-patient-drug-information\" class=\"drug drug_patient\">Sildenafil: Patient drug information</a></li></ul></div></div>","javascript":null}